Clinical trials: Glabellar Lines
Glabellar Frown Lines
Subject Satisfaction With AbobutulinumtoxinA Treatment
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
- Trial name
- DREAM (NCT03687736)
- Testing
- AbobotulinumtoxinA
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
- Trial name
- NCT03004248
- Testing
- Botulinum Toxins, Type A
- Where
- 61 sites in United States, Canada
- Volunteers
- 2,691 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05248867
- Testing
- AGN-151586
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 638 people
- Sponsor
- AbbVie
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01189760
- Testing
- onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 917 people
- Sponsor
- Allergan
Glabellar Frown Lines, Canthal Lines
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
This study to assess aesthetic improvement following treatment with QM1114-DP.
- Trial name
- NCT05148000
- Testing
- QM1114-DP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
AI-09 In Subjects With Glabellar Lines, GL-101
AI-09 In Subjects with Glabellar Lines
- Trial name
- NCT05565950
- Testing
- AI-09, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eirion Therapeutics Inc.
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL)…
- Trial name
- NCT04259086
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 8 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Furrows
Botox Cosmetic and the Young Patient With Glabellar Furrows
The purpose of this study is to see if consistent treatment with Botox will lead to longer lasting effects. Botox is an injectable liquid that is approved by the U.S.
- Trial name
- NCT00856999
- Testing
- Botox
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Glabellar Lines
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with botulinum toxin.
- Trial name
- NCT05248893
- Testing
- AGN-151586
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 992 people
- Sponsor
- AbbVie
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01224015
- Testing
- normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- Allergan
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.
- Trial name
- NCT03721016
- Testing
- MT10109L
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 415 people
- Sponsor
- Medy-Tox
Moderate to Severe Glabellar Frown Lines
Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
The purpose of the study is to investigate the safety and duration of effect following different doses of Botulinum Toxin A (NT 201) in the treatment of glabellar frown lines (GFL).
- Trial name
- NCT03806933
- Testing
- NT 201
- Where
- 9 sites in United States, Germany
- Volunteers
- 241 people
- Sponsor
- Merz Aesthetics GmbH
Glabellar Lines
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
This study will evaluate the safety and efficacy of two different types of botulinum toxin type A for the treatment of glabellar frown lines.
- Trial name
- NCT01271452
- Testing
- botulinum toxin type A
- Where
- Germany
- Volunteers
- 224 people
- Sponsor
- Allergan
Glabellar Frown Lines
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
The purpose of this study is to find an optimal dose to determine the safety and tolerability of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular injection in subjects with glabellar lines…
- Trial name
- NCT01485601
- Testing
- MT10109
- Where
- Australia
- Volunteers
- 121 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- NCT02334423
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05248880
- Testing
- AGN-151586
- Where
- 17 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- AbbVie
Glabellar Rhytides
Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial laser resurfacing.
- Trial name
- NCT01814670
- Testing
- botulinum toxin Type A
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Allergan
Upper Facial Rhytides, Crow's Feet Lines
BOTOX® in the Treatment of Upper Facial Lines in Japan
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).
- Conditions
- Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines
- Trial name
- NCT01797094
- Testing
- botulinum toxin Type A (44U), botulinum toxin Type A (32U)
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Allergan